BUSINESSQUARTZ
Roche is striking a $2.3 billion deal with Nurix Therapeutics to develop a blood cancer drug
Roche is entering a $2.3 billion deal with Nurix Therapeutics to develop bexobrutideg, an oral BTK degrader. Nurix receives $700 million upfront for co-developing the drug targeting chronic lymphocytic leukemia and other diseases.
Mentioned
Related Signal
Adjacent reporting
- Incyte strikes up to $2bn deal for blood disorder biotech
- China’s Innovent Biologics signs US$10.5 billion Pfizer deal for 12 cancer drug trials
- China’s Innovent Biologics signs US$10.5 billion Pfizer deal for 12 cancer drug trials
- China's Innovent Biologics signs drug deal with Pfizer worth up to $10.5bn
- STAT+: Bristol Myers Squibb partners with China’s Hengrui Pharma on a dozen drugs
- Johnson & Johnson is buying cancer drug biotech Firefly Bio for $1 billion